Vivian P. Bykerk, MD, FRCPC
In this video, Vivian P. Bykerk, MD, FRCPC, rheumatologist and director of the Inflammatory Arthritis Center of Excellence at Hospital for Special Surgery, and professor of medicine at Weill Cornell University, discussed:
- safety and efficacy data on JAK inhibitors presented at ACR 2020;
- her position on JAK inhibitors vs. biologics if a patient has methotrexate inadequate response (MTXIR);
- deciding between JAK inhibitors for different patients, particularly in the COVID-19 pandemic when it’s important to get patients off of steroids; and
- areas of future research, such as combining a JAK inhibitor with a biologic, developing agents that can safely inhibit more than one pathway and advancing precision medicine approaches.
Click Here to Manage Email Alerts